BCV and BCVR immunogens effectively controlled Trypanosoma cruzi replication and blocked myocarditis, cardiac fibrosis, and left ventricular dysfunction in Chagas disease.
Do BCVR and BCV immunogens control Trypanosoma cruzi infection and prevent Chagasic cardiomyopathy and left ventricular dysfunction?
BCVR and BCV immunogens effectively control T. cruzi infection and prevent the development of Chagasic cardiomyopathy and left ventricular dysfunction.
Absolute Event Rate: 0% vs 0%
BCVR and BCV (bicistronic immunogen with and without RIG-I adjuvant) immunogens were designed in compliance with Food and Drug Administration guidelines. These immunogens were nontoxic, and highly effective in controlling the replication and persistence of Trypanosoma cruzi. Importantly, BCV/BCVR blocked the myocarditis, cardiac fibrosis, and left ventricular dysfunction that otherwise contribute to heart failure and sudden death in Chagas disease.
Lokugamage et al. (Sun,) reported a other. BCV and BCVR immunogens effectively controlled Trypanosoma cruzi replication and blocked myocarditis, cardiac fibrosis, and left ventricular dysfunction in Chagas disease.